Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat Doses of SB-728mR-T in HIV-Infected Subjects
NCT02225665Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Aug 2014
- Primary completion
- Jun 2018
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SB-728mR-T in human immunodeficiency virus infection (HIV), sponsored by Sangamo Therapeutics. Started Aug 2014; status: completed.
02
Drugs
SB-728mR-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02225665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225665.